Diagnostic value of female genital malignant tumors by using 111In-bleomycin scintigraphy.
In order to know if it is possible to objectively decide the extent of infiltration of female genital malignant tumors into parametrium by using 111In-bleomycin scintigraphy, a fundamental and clinical investigation was made. The result was as follows; 1) The radiochemical purity and stability of 111In-BLM were comparatively unchangeable. When this complex was kept at room temperature for a week, there was not more than 2% of the free 111In. 2) As to blood clearance, when the blood radioactivity of 111In-BLM 5 minutes after the injection was counted as 100%, about 80% of the radioactivity was cleared from the blood in 48 hours. Over 50% of the radioactivity was excreted into the urine in 48 hours. 3) Of 29 cases of female genital malignant tumors, 23 cases (79%) showed positive images. Therefore 111In-BLM was found to be one of the suitable radiopharmaceuticals for the diagnosis of female genital malignant tumors. 4) 111In-BLM scintigraphy was of great use for deciding the extent of the invasion of carcinoma cervicis uteri into parametrium and for the search of metastasis.
D000328:Adult; D000368:Aged; D001761:Bleomycin; D004341:Drug Evaluation; D004355:Drug Stability; D005260:Female; D005833:Genital Neoplasms, Female / Q000000981:diagnostic imaging*; D006801:Humans; D007204:Indium; D008875:Middle Aged; D011868:Radioisotopes; D011877:Radionuclide Imaging
D011868:Radioisotopes; D007204:Indium; D001761:Bleomycin